David Lubner

David Lubner is a senior finance executive with more than 25 years of experience in the life sciences industry. David served as Executive Vice President and Chief Financial Officer of Ra Pharma until May 2020 following its acquisition by UCB. Prior to Ra Pharma, he was Senior Vice President and Chief Financial Officer of Tetraphase Pharmaceuticals and was previously Chief Financial Officer of PharMetrics Inc., a leading patient-based pharmacy and medical claims data informatics company. He was also Chief Financial Officer at ProScript, where Velcade® (bortezomib), a therapy widely used for the treatment of the blood cancer multiple myeloma, was discovered.

David serves on the Board of Directors of Dyne Therapeutics, Therapeutics Acquisition Corp. (Nasdaq: TXAC), Gemini Therapeutics, and Ichnos Sciences. A Certified Public Accountant, Mr. Lubner received his BS in business administration from Northeastern University and an MS in taxation from Bentley University.